{
    "clinical_study": {
        "@rank": "131117", 
        "arm_group": {
            "arm_group_label": "Study population", 
            "description": "Single cohort of dialysis patients"
        }, 
        "brief_summary": {
            "textblock": "An observational study to describe the treatment of anaemia in patients with chronic kidney\n      disease, who are receiving dialysis treatment at selected study centres in South Africa."
        }, 
        "brief_title": "Study of South African Dialysis Patients", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Kidney Disease, Receiving Dialysis", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This multicentre, prospective, observational study will describe the treatment and clinical\n      outcomes of of dialysis patients in South Africa.  No formal hypothesis will be tested in\n      this descriptive study.  Eligible subjects will be receiving either peritoneal or\n      haemodialysis, will have received Aranesp therapy between 3 and 6 months prior to enrolment\n      into the study, do not need to be receiving Aranesp at the time of enrolment and will be\n      followed for up to 12 months after commencement of Aranesp.  Data to be collected includes\n      ESA therapies, iron usage, relevant concomitant therapies, haemoglobin concentrations, other\n      relevant clinical laboratory parameters and red cell transfusions."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients undergoing chronic haemodialysis or peritoneal dialysis\n\n          -  Commenced Aranesp therapy 3-6 months prior to enrolment\n\n          -  Erythropoiesis stimulating agent (ESA) naive or treated with another ESA prior to\n             commencing Aranesp\n\n          -  Informed consent obtained\n\n        Exclusion Criteria:\n\n          -  Received Aranesp in an interventional study within 6 months prior to start of\n             observation period\n\n          -  Receive investigational product during the observation period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult patients receiving dialyis at South African study centres and having received at\n        least one dose of Aranesp"
            }
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01890577", 
            "org_study_id": "20110243"
        }, 
        "intervention": {
            "arm_group_label": "Study population", 
            "description": "Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.", 
            "intervention_name": "Aranesp", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Darbepoetin alfa", 
                "Hematinics"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chronic kidney disease", 
            "Dialysis", 
            "Erythropoiesis stimulating agent", 
            "South Africa"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Glenwood", 
                        "country": "South Africa", 
                        "state": "KwaZulu-Natal", 
                        "zip": "4083"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Umhlanga Rocks", 
                        "country": "South Africa", 
                        "state": "KwaZulu-Natal", 
                        "zip": "4320"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "state": "Western Cape", 
                        "zip": "7800"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durban", 
                        "country": "South Africa", 
                        "zip": "4001"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kimberley", 
                        "country": "South Africa", 
                        "zip": "8300"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lenasia", 
                        "country": "South Africa", 
                        "zip": "1821"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roodepoort", 
                        "country": "South Africa", 
                        "zip": "1709"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational Study of South African Dialysis Patients Treated With Aranesp", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "South Africa: Medicines Control Council", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Haemoglobin concentration", 
            "safety_issue": "No", 
            "time_frame": "Reported as the mean of all available values for each 4-week period for the duration of the individual study period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01890577"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Hb <10g/dL ; Hb >12g/dL", 
                "measure": "Haemoglobin excursions", 
                "safety_issue": "No", 
                "time_frame": "On a continuous basis over individual 15-month observation period up"
            }, 
            {
                "description": "Hb 10-12g/dL", 
                "measure": "Haemoglobin within range", 
                "safety_issue": "No", 
                "time_frame": "On a continuous basis over individual 15-month observation period"
            }, 
            {
                "description": "Type", 
                "measure": "Erythropoiesis stimulating agent (ESA) usage", 
                "safety_issue": "No", 
                "time_frame": "On a continuous basis over individual 15-month observation period"
            }, 
            {
                "description": "Ratio of the calculated mean weekly dose equivalent of an ESA administered immediately prior to conversion to treatment with Aranesp, to the calculated mean weekly dose equivalent of the first dose of Aranesp administered at commencement. This secondary outcome measure is not applicable to subjects who are ESA-naive at time of Aranesp commencement.", 
                "measure": "ESA/Aranesp dose ratio", 
                "safety_issue": "No", 
                "time_frame": "Day of commencement of Aranesp"
            }, 
            {
                "description": "Dose", 
                "measure": "Iron therapy use", 
                "safety_issue": "No", 
                "time_frame": "On a continuous basis over individual 15-month observation period"
            }, 
            {
                "description": "Type", 
                "measure": "Use of concomitant therapies: Immunosuppressants, cardiovascular medications, secondary hypoparathyroidism medications, anti-retroviral therapy", 
                "safety_issue": "No", 
                "time_frame": "Usage recorded at each 12-week interval over the individual observation period"
            }, 
            {
                "description": "Concentration", 
                "measure": "C-Reactive protein, albumin, transferrin saturation and serum ferritin", 
                "safety_issue": "No", 
                "time_frame": "As available over individual 15-month observation period"
            }, 
            {
                "description": "Number of red cell transfusions", 
                "measure": "Red cell transfusions", 
                "safety_issue": "No", 
                "time_frame": "As occurring over individual 15-month observation period"
            }, 
            {
                "description": "Dates and duration of hospital admissions", 
                "measure": "Hospitalisation", 
                "safety_issue": "No", 
                "time_frame": "As occurring over individual 15-month observation period"
            }, 
            {
                "description": "Dose", 
                "measure": "ESA usage", 
                "safety_issue": "No", 
                "time_frame": "On a continuous basis over individual 15-month observation period"
            }, 
            {
                "description": "Type", 
                "measure": "Iron therapy use", 
                "safety_issue": "No", 
                "time_frame": "On a continuous basis over individual 15-month observation period"
            }, 
            {
                "description": "Dosing frequency", 
                "measure": "Iron therapy use", 
                "safety_issue": "No", 
                "time_frame": "On a continuous basis over individual 15-month observation period"
            }, 
            {
                "description": "Route of administration", 
                "measure": "Iron therapy use", 
                "safety_issue": "No", 
                "time_frame": "On a continuous basis over individual 15-month observation period"
            }, 
            {
                "description": "Dosing frequency", 
                "measure": "ESA usage", 
                "safety_issue": "No", 
                "time_frame": "On a continuous basis over individual 15-month observation period"
            }, 
            {
                "description": "Number of units transfused", 
                "measure": "Red cell transfusions", 
                "safety_issue": "No", 
                "time_frame": "As occurring over individual 15-month observation period"
            }, 
            {
                "description": "Number of days spent in Intensive Care Unit", 
                "measure": "Hospitalisation", 
                "safety_issue": "No", 
                "time_frame": "As occurring over individual 15-month observation period"
            }, 
            {
                "description": "Primary reason for admission; final diagnosis", 
                "measure": "Hospitalisation", 
                "safety_issue": "No", 
                "time_frame": "As occurring over individual 15-month observation period"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014", 
        "why_stopped": "Administrative Decision by Amgen"
    }
}